Healthcare / Medical Instruments & SuppliesKuala Lumpur
$0.04
+0.00 (+14.29%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-35.5M · quality 61.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
25/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$16M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-25.1%
↓Gross Margin
18.8%
↓Debt/Equity
0.47
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-12.9%
FCF CAGR
—
FCF margin
-7.9%
FCF / Net income
0.17x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $56.5M · net income $-26.5M · FCF $-4.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $56.5M | $56.5M | $47.6M | $44.6M | $85.4M |
| Net Income | $-26.5M | $-26.5M | $-41.3M | $-7.0M | $1.1M |
| EBITDA | $-17.8M | $-17.8M | $-34.6M | $3.3M | $3.6M |
| EPS | — | — | -0.11 | -0.02 | 0.01 |
| Gross Margin | 18.8% | 18.8% | 23.2% | 35.9% | 15.8% |
| Operating Margin | -39.5% | -39.5% | -79.7% | -4.2% | -2.8% |
| Net Margin | -46.9% | -46.9% | -86.8% | -15.7% | 1.3% |
| Balance Sheet | |||||
| Debt/Equity | 0.47 | 0.47 | 0.41 | 0.19 | 0.07 |
| Current Ratio | 1.13 | 1.13 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-4.5M | $-4.5M | $-35.5M | $-42.1M | $-39.3M |
| Returns | |||||
| ROE | -25.1% | -25.1% | -31.7% | -4.1% | 0.7% |
| Valuation | |||||
| P/E | — | — | — | — | 20.83 |
| EV/EBITDA | — | — | — | 21.67 | 6.74 |
| P/B | 0.15 | 0.15 | 0.33 | 0.29 | 0.15 |
| Growth & Yield | |||||
| Revenue Growth | 18.6% | 18.6% | 6.8% | -47.8% | — |
| EPS Growth | — | — | -388.1% | -297.5% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-42.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.11 → n/d
Residual
-42.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.